GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Cash Flow for Lease Financing

Pharmesis International (SGX:BFK) Cash Flow for Lease Financing : S$-0.11 Mil (TTM As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International Cash Flow for Lease Financing?

Pharmesis International's Cash Flow for Lease Financing for the six months ended in Dec. 2024 was S$-0.08 Mil. Pharmesis International's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2024 was S$-0.11 Mil.

Compared with last quarter (S$-0.04 Mil in Jun. 2024 ), Pharmesis International's Cash Flow for Lease Financing remained the same in Dec. 2024 (S$-0.08 Mil).

Pharmesis International Cash Flow for Lease Financing Historical Data

The historical data trend for Pharmesis International's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International Cash Flow for Lease Financing Chart

Pharmesis International Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.06 -0.12 -0.04 -0.11

Pharmesis International Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.04 - -0.04 -0.08

Pharmesis International Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Pharmesis International's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmesis International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Cash Flow for Lease Financing
Comparable Companies
SGX:42C ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904
Traded in Other Exchanges
N/A
Address
5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Website
https://www.pharmesis.com
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.